Please login to the form below

Not currently logged in
Email:
Password:

LixiLan

This page shows the latest LixiLan news and features for those working in and with pharma, biotech and healthcare.

Sanofi wins EU approval for new diabetes combination Suliqua

Sanofi wins EU approval for new diabetes combination Suliqua

Approval of the once-daily injection was based on two phase III studies - LixiLan-O and LixiLan-L - which showed Suliqua to be statistically superior in reducing blood sugar levels in

Latest news

  • FDA clears rival diabetes combos from Sanofi and Novo Nordisk FDA clears rival diabetes combos from Sanofi and Novo Nordisk

    In almost a mirror image, Sanofi's Soliqua (variously known as iGlarLixi and LixiLan) combines top-selling basal insulin Lantus (insulin glargine) – albeit now facing biosimilar competition in some markets - and

  • Sanofi trumpets new IGlarLixi data after regulatory delay Sanofi trumpets new IGlarLixi data after regulatory delay

    Prior results from the LixiLan-L trial have shown that the combination is more effective than Lantus in controlling haemoglobin A1c levels, a biomarker for glucose control over time.

  • Sanofi boosted by iGlarLixi trials at ADA Sanofi boosted by iGlarLixi trials at ADA

    Sanofi's combination insulin/GLP-1 agonist drug iGlarLixi (formerly LixiLan) has met objectives in two phase III trials, setting up a showdown in the diabetes market. ... The LixiLan-O trial compared the once-daily combination injection with either

  • Sanofi takeover bid rebuffed by Medivation Sanofi takeover bid rebuffed by Medivation

    However, it is going through a fertile stage at present, with recent approvals for cholesterol drug Praluent (alirocumab) and dengue fever vaccine Dengvaxia and new diabetes hope LixiLan (lixisenatide/insulin glargine)

  • Sanofi uses priority review voucher for diabetes combo Sanofi uses priority review voucher for diabetes combo

    Sanofi has used an FDA priority review voucher for diabetes combination LixiLan, trying to get its nose in front in a race to market with Novo Nordisk. ... With $8bn-a-year Lantus already facing biosimilar competition in some markets, LixiLan is seen as

More from news
Approximately 3 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics